Contact Us
Drug Search Results
More Filters [+]

BIIB-101

Alternative Names: biib-101, biib 101, biib101, ion464, ion 464, ion-464, IONIS-BIIB6Rx
Latest Update: 2025-01-13
Latest Update Note: News Article

Product Description

ION464, also known as BIIB101, is an investigational antisense medicine designed to inhibit the production of the alpha-synuclein protein as a potential therapy for Parkinson’s disease (PD), multiple system atrophy (MSA) and related synucleinopathies. (Sourced from: https://www.ionispharma.com/medicines/ionis-biib6/)

Mechanisms of Action: aSYN Inhibitor

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ionis
Company Location: CARLSBAD CA 92010
Company CEO: Brett P. Monia
Additonal Commercial Interests: Biogen

Clinical Description

Map of Global Clinical Trials for BIIB-101

Countries in Clinic: Austria, France, Germany, Portugal, United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Multiple System Atrophy|Shy-Drager Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
HORIZON

P1

Recruiting

Multiple System Atrophy|Shy-Drager Syndrome

2027-09-01

Recent News Events

Date

Type

Title

01/13/2025

News Article

 Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

01/13/2021

News Article

 Multiple System Atrophy Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions